ArticleEmerging microbes & infections2021
Identification of a blockade epitope of human norovirus GII.17.
Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Emergence of a novel GII.17 variant is associated with immune evasion rather than an altered HBGA-binding profile.PLoS pathogens · 2026Article
- Characterization of high affinity IgM and IgG monoclonal antibodies against norovirus variants GII.4 and GII.17.Protein science : a publication of the Protein Society · 2026Article
- GII.17 norovirus re-emerged in the 2020s as a result of dynamic and adaptive evolutionary processes.Nature communications · 2025Article
- Increased GII.3[P12] norovirus outbreaks and viral whole genome analysis in Beijing, China during 2021 and 2023.Gut pathogens · 2025Article
- Appearance and spread of norovirus genotype GII.17 subcluster C2 (Romania-2021 like) in Nizhny Novgorod, Russia, 2021-2023.Archives of virology · 2025Article
- The saga to monitor and control norovirus: the rise of GII.17.The Journal of general virology · 2025Review
- Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirus.Virology journal · 2025Article
- Vaccinia Virus Vector Bivalent Norovirus Vaccine.Viruses · 2025Article
- Graphene-Based Virus Enrichment Protocol Increases the Detection Sensitivity of Human Norovirus in Strawberry and Oyster Samples.Foods (Basel, Switzerland) · 2024Article
- Identification of a GII.6 norovirus blockade antibody epitope.Virus research · 2023Article
- Linear epitopes on the capsid protein of norovirus commonly elicit high antibody response among past-infected individuals.Virology journal · 2023Article
- Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters.Frontiers in immunology · 2023Article
- Rapid screening for antigenic characterization of GII.17 norovirus strains with variations in capsid gene.Gut pathogens · 2022Article
- A Bibliometric Analysis of the Literature on Norovirus Disease from 1991-2021.International journal of environmental research and public health · 2022Article
- 6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice.Frontiers in immunology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human noroviruses are the dominant causative agent of acute viral gastroenteritis worldwide. During the winter of 2014-2015, genotype GII.17 cluster IIIb strains emerged as the leading cause of norovirus infection in Asia and later spread to other parts of the world. It is speculated that mutation at blockade epitopes may have resulted in virus escape from herd immunity, leading to the emergence of GII.17 cluster IIIb variants. Here, we identify a GII.17 cluster IIIb-specific blockade epitope by monoclonal antibody (mAb)-based epitope mapping. Four mAbs (designated as M1 to M4) were generated from mice immunized with virus-like particle (VLP) of a GII.17 cluster IIIb strain. Among them, M1 and M3 reacted specifically with the cluster IIIb VLP but not with the VLPs from clusters II or IIIa. Moreover, M1 and M3 dose-dependently blocked cluster IIIb VLP binding with its ligand, histo-blood group antigens (HBGAs). Epitope mapping revealed that M1 and M3 recognized the same highly exposed epitope consisting of residues 293-296 and 299 in the capsid protein VP1. Sequence alignment showed that the M1/M3 epitope sequence is highly variable among different GII.17 clusters whereas it is identical for cluster IIIIb strains. These data define a dominant blockade epitope of GII.17 norovirus and provide evidence that blockade epitope evolution contributes to the emergence of GII.17 cluster IIIb strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.